U.S. Markets close in 5 hrs 1 min

Interpace Biosciences, Inc. (IDXG)

NasdaqGS - NasdaqGS Delayed Price. Currency in USD
Add to watchlist
6.17-0.23 (-3.59%)
As of 10:56AM EDT. Market open.

Interpace Biosciences, Inc.

Morris Corporate Center 1
Building C 300 Interpace Parkway
Parsippany, NJ 07054
United States
855 776 6419
http://www.interpace.com

Sector(s)Healthcare
IndustryDiagnostics & Research
Full Time Employees176

Key Executives

NameTitlePayExercisedYear Born
Mr. Jack E. StoverCEO, Pres & Director475.05kN/A1953
Mr. Gregory RichardSr. VP & Chief Commercial Officer320.55kN/A1967
Mr. Fred S. KnechtelCFO, Treasurer & Company Sec.N/AN/A1961
Mr. Glenn GershonSr. VP of OperationsN/AN/AN/A
Mr. Thomas John FreeburgChief Accounting OfficerN/AN/A1968
Amounts are as of December 31, 2019 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

Interpace Biosciences, Inc. provides molecular diagnostic tests, bioinformatics, and pathology services for evaluating cancer risk in the United States. The company offers PancraGEN, a pancreatic cyst and pancreaticobiliary solid lesion genomic test that helps physicians better assess risk of pancreaticobiliary cancers using its PathFinderTG platform; and ThyGeNEXT, an oncogenic mutation panel to identify malignant thyroid nodules. It also provides ThyraMIR assesses thyroid nodules for risk of malignancy utilizing a proprietary microRNA gene-expression assay; and RespriDx, a genomic test that helps physicians to differentiate metastatic or recurrent lung cancer. The company also provides pharmacogenomics testing, genotyping, biorepository, and other customized services to the pharmaceutical and biotech industries. It primarily serves physicians, hospitals, and clinics. The company was formerly known as Interpace Diagnostics Group, Inc. and changed its name to Interpace Biosciences, Inc. in November 2019. Interpace Biosciences, Inc. was incorporated in 1986 and is headquartered in Parsippany, New Jersey.

Corporate Governance

Interpace Biosciences, Inc.’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.